Streetbeat News

Products Services

JAGX

Jaguar Health, Inc. (NASDAQ:JAGX) has entered into a 5-year exclusive in-license agreement with Venture Life Group PLC for the FDA-approved oral mucositis product, Gelclair, targeting the U.S. market. Gelclair, aimed at managing pain and providing relief for oral mucositis patients, marks Jaguar's expansion into cancer supportive care. The commercial launch is planned for Q3 2024. Oral mucositis is a common side effect of cancer treatments, affecting up to 40% of chemotherapy patients and 90% of those with head and neck cancers undergoing chemotherapy and radiotherapy.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:35 pm

SSYS

Stratasys has signed an agreement to become the exclusive polymer 3D printing partner of Select Additive Technologies, marking the first time the largest machine tool reseller in the US will offer additive manufacturing benefits to its extensive customer base.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:25 pm

BLND

Michigan Schools and Government Credit Union (MSGCU) has chosen Blend's cloud banking services to improve its digital lending experience. This partnership will focus on enhancing the mortgage, income, close, and home equity solutions for MSGCU, aiming to simplify the application process, automate lender workflows, and ensure a consistent digital experience across its real estate business.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:22 pm

OPTT

Ocean Power Technologies, Inc. (OPTT) has entered into a teaming agreement with a major international defense contractor to deploy its Maritime Domain Awareness Solutions (MDAS) in certain geographic regions. This collaboration aims to enhance maritime security and surveillance capabilities through OPT's innovative technology and the contractor's defense expertise. No financial terms of the agreement were disclosed.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:21 pm

TEVA

Teva Pharmaceuticals announced positive final results from the Phase 4 START study of AUSTEDO's 4-week Titration Kit for Huntington's disease (HD) chorea at the 2024 AAN Annual Meeting. The study showed that nearly 80% of patients achieved optimal dosing within four weeks, with significant improvements in symptoms and high patient satisfaction. AUSTEDO is highlighted as the only VMAT2 inhibitor with 3-year data for HD chorea, emphasizing its real-world effectiveness, safety, and adherence.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:18 pm

AMRX

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) launched PEMRYDI RTU, the first ready-to-use pemetrexed injectable for non-squamous non-small cell lung cancer and malignant pleural mesothelioma, eliminating the need for reconstitution, dilution, or refrigeration. This launch is part of Amneal's strategy to release two to three branded oncology 505(b)(2) products annually, starting in 2024. PEMRYDI RTU has a unique J-Code (J9324) for reimbursement and is available in two vial sizes. It's indicated for use with pembrolizumab and platinum chemotherapy or cisplatin. U.S. annual sales for pemetrexed were $287 million for the 12 months ending February 2024.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:16 pm

PRPH

ProPhase Labs, Inc. (NASDAQ:PRPH) announced the launch of Project ZenQ-AI, a new initiative in cancer treatment research leveraging its AI platform, extensive genomics database, and patented insights into esophageal cancer for the development of Antibody Drug Conjugates (ADCs). The project aims to utilize whole genome sequencing data from over 130 countries and the BE-Smart Test for esophageal adenocarcinoma to identify ADC candidates, promising more effective and personalized cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:15 pm

LSEA

Landsea Homes has introduced 'Landsea Elements', a suite of exclusive financial services aimed at providing end-to-end support for its homebuyers. This includes the launch of Landsea Insurance Agency, complementing the existing services of Landsea Mortgage and Landsea Title.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:07 pm

NSANY

TM

TSLA

Nissan Motor Co plans to adopt gigacasting, a technique popularized by Tesla Inc, to produce components for its electric vehicles, aiming to reduce manufacturing costs by 10% and achieve cost parity between electric and traditional vehicles by 2030. This move is part of Nissan's strategy to enhance competitiveness in the EV market. Toyota Motor Corp has also committed to adopting gigacasting, indicating its industry-wide appeal.

Portfolio Pulse from Shivani Kumaresan

April 16, 2024 | 12:06 pm